BACKGROUND AND STUDY AIMS: Helicobacter pylori eradication rates with standard triple therapy have declined to unacceptable levels. This randomized trial aimed at evaluating the efficacy of a ciprofloxacin containing sequential regimen in the eradication of H. pylori-infected patients vs. a clarithromycin containing sequential therapy. METHODS: A total of 212 patients were randomized into 14-day therapeutic schemes (106 patients per group): (1) clarithromycin-containing sequential therapy rabeprazole plus amoxicillin for 7 days, followed by rabeprazole plus clarithromycin plus metronidazole for 7 days, and (2) ciprofloxacin-containing sequential therapy using ciprofloxacin instead of clarithromycin. Eradication was confirmed by stool H. pylori antigen. Adverse effects and compliance were assessed by a questionnaire. RESULTS:Per protocol cure rates were as follows: 87.6 % in the ciprofloxacin-containing sequential therapy and 76 % in the clarithromycin group. Intention-to-treat cure rates were as follows: 73.5 % for the ciprofloxacin group and 66 % for the clarithromycin group. No differences in compliance or adverse effects were demonstrated among treatments. CONCLUSION:Ciprofloxacin-containing sequential therapy is more effective and equally safe compared to a clarithromycin-containing sequential therapy.
RCT Entities:
BACKGROUND AND STUDY AIMS: Helicobacter pylori eradication rates with standard triple therapy have declined to unacceptable levels. This randomized trial aimed at evaluating the efficacy of a ciprofloxacin containing sequential regimen in the eradication of H. pylori-infectedpatients vs. a clarithromycin containing sequential therapy. METHODS: A total of 212 patients were randomized into 14-day therapeutic schemes (106 patients per group): (1) clarithromycin-containing sequential therapy rabeprazole plus amoxicillin for 7 days, followed by rabeprazole plus clarithromycin plus metronidazole for 7 days, and (2) ciprofloxacin-containing sequential therapy using ciprofloxacin instead of clarithromycin. Eradication was confirmed by stool H. pylori antigen. Adverse effects and compliance were assessed by a questionnaire. RESULTS: Per protocol cure rates were as follows: 87.6 % in the ciprofloxacin-containing sequential therapy and 76 % in the clarithromycin group. Intention-to-treat cure rates were as follows: 73.5 % for the ciprofloxacin group and 66 % for the clarithromycin group. No differences in compliance or adverse effects were demonstrated among treatments. CONCLUSION:Ciprofloxacin-containing sequential therapy is more effective and equally safe compared to a clarithromycin-containing sequential therapy.
Authors: J Molina-Infante; B Perez-Gallardo; M Fernandez-Bermejo; M Hernandez-Alonso; G Vinagre; C Dueñas; J M Mateos-Rodriguez; G Gonzalez-Garcia; E G Abadia; J P Gisbert Journal: Aliment Pharmacol Ther Date: 2010-02-20 Impact factor: 8.171
Authors: A Zullo; D Vaira; N Vakil; C Hassan; L Gatta; C Ricci; V De Francesco; M Menegatti; A Tampieri; F Perna; V Rinaldi; F Perri; C Papadìa; F Fornari; S Pilati; L S Mete; A Merla; R Potì; G Marinone; A Savioli; S M A Campo; D Faleo; E Ierardi; M Miglioli; S Morini Journal: Aliment Pharmacol Ther Date: 2003-03-01 Impact factor: 8.171
Authors: Javier P Gisbert; Xavier Calvet; Anthony O'Connor; Francis Mégraud; Colm A O'Morain Journal: J Clin Gastroenterol Date: 2010 May-Jun Impact factor: 3.062